Skip to content
Companies

HCW Biologics

Fusion protein drugs for inflammation-driven disease

Raised to date

$4M

of $4M offered across 1 Form D filing

Investors
7
Last filed
Jun 8, 2026

About

HCW Biologics is a clinical-stage biopharmaceutical company in Miramar, Florida developing fusion immunotherapeutics for diseases driven by chronic, low-grade inflammation, or inflammaging. Its TOBI (Tissue factOr-Based fusIon) discovery platform is used to build multi-functional fusion proteins that combine several immune-modulating activities in a single molecule. Lead candidate HCW9218 is a bifunctional immunotherapeutic that neutralizes TGF-beta while stimulating immune cells, in Phase 1b/2 study in pancreatic cancer; HCW9302 is an IL-2 fusion protein complex in a Phase 1 trial for alopecia areata. The company was founded in 2018 by Hing C. Wong and is publicly traded on Nasdaq under the ticker HCWB.

The TOBI platform uses a tissue-factor-based scaffold to fuse multiple immune-modulating domains into one molecule, letting a single drug both suppress an immunosuppressive signal and stimulate immune effector cells, and the company targets senescence and inflammaging rather than only oncology.

Funding

  • EquityFiled Jun 8, 2026Form D
    $4M/ $4M

Product

HCW9218

Clinical-stage biologic drug candidate

A bifunctional fusion immunotherapeutic built on the TOBI platform that neutralizes transforming growth factor beta while stimulating immune cells, currently in a Phase 1b/2 clinical study in pancreatic cancer.

  • Bifunctional design built on the TOBI (Tissue factOr-Based fusIon) scaffold
  • TGF-beta neutralization combined with immune cell stimulation
  • In Phase 1b/2 clinical study for pancreatic cancer

Built for

Patients with cancer, autoimmune disease and other conditions promoted by chronic inflammation, reached through oncologists and specialist physicians, plus cell and gene therapy manufacturers who buy its reagent molecules

People on file